Search

Jennifer E Visich

from Boulder, CO
Age ~56
Get Report
Also known as:
Jennifer Emily Visich, Jennifer D Visich, Jennifer E Dyess, Jennifer E Dayes, Visich E Jennifer
Phone and address:
330 Dewey Ave, Boulder, CO 80304
Related to:
Maryanne Anne Ismael, 69Nancy Jacquelyne North, 66Visich E JenniferPatricia A Visich, 68Michael Henry Visich, 70Marianne C Visich, 70Marianne VisichJacqui North, 65Mary R Visich, 97Frank J Visich, 72
Connected to:
Alexandra Visick, 46Ryan F Visina, 62Maria P Visinho, 61Joseph J Visinsky, 45Melissa L Visinski, 36Elisabeth C Visintainer, 64Jacqueline L Visintainer, 87Mark E Visintainer, 63Patricia E Visintainer, 59Frank D Visintini, 59

Jennifer Visich Phones & Addresses

  • 330 Dewey Ave, Boulder, CO 80304
  • Telluride, CO
  • Winthrop, WA
  • Seattle, WA
  • San Francisco, CA
  • West Chester, PA
  • Richmond, VA
  • Santa Fe, NM
  • South San Francisco, CA

Work

Company: Unity biotechnology Apr 2019 Position: Vice president, translational and quantitative sciences

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Virginia Commonwealth University 1990 to 1996

Skills

Drug Development • Clinical Development • Pharmacokinetics • Pharmacodynamics • Clinical Trials • Clinical Research • Clinical Pharmacology • Biotechnology • Inflammation • Oncology • Therapeutic Areas • Biomarkers • Hematology • Translational Medicine • Pharmacology • Pharmaceutical Industry • Immunology • Drug Discovery • Protein Chemistry • Monoclonal Antibodies • Pharmaceutics • Biopharmaceuticals • Biologics • Fda • Regulatory Submissions • Ind • U.s. Food and Drug Administration

Industries

Biotechnology

Public records

Vehicle Records

Jennifer Visich

View page
Address:
978 Elizabeth St, San Francisco, CA 94114
Phone:
(415) 794-2403
VIN:
WAUKD78P38A075737
Make:
AUDI
Model:
A3
Year:
2008

Resumes

Resumes

Jennifer Visich Photo 1

Vice President, Translational And Quantitative Sciences

View page
Location:
330 Dewey Ave, Boulder, CO 80304
Industry:
Biotechnology
Work:
Unity Biotechnology
Vice President, Translational and Quantitative Sciences
Unity Biotechnology
Executive Director, Quantitative Sciences
Certara Sep 2016 - Mar 2018
Executive Director, Certara Strategic Consulting Clinical Pharmacology, Modeling and Simulation
Amgen Apr 2015 - Aug 2016
Director, Clinical Pharmacology and Modeling and Simulation
Genentech Jun 2007 - Mar 2015
Associate Director and Senior Scientist, Clinical Pharmacology
Education:
Virginia Commonwealth University 1990 - 1996
Doctorates, Doctor of Philosophy James Madison University 1986 - 1990
Bachelors, Bachelor of Science, Chemistry
Skills:
Drug Development
Clinical Development
Pharmacokinetics
Pharmacodynamics
Clinical Trials
Clinical Research
Clinical Pharmacology
Biotechnology
Inflammation
Oncology
Therapeutic Areas
Biomarkers
Hematology
Translational Medicine
Pharmacology
Pharmaceutical Industry
Immunology
Drug Discovery
Protein Chemistry
Monoclonal Antibodies
Pharmaceutics
Biopharmaceuticals
Biologics
Fda
Regulatory Submissions
Ind
U.s. Food and Drug Administration

Publications

Us Patents

Dosing Methods For Treating Autoimmune Diseases Using A Taci-Ig Fusion Protein Such As Atacicept

View page
US Patent:
20090186040, Jul 23, 2009
Filed:
Jun 13, 2008
Appl. No.:
12/139078
Inventors:
Sharon J. Busby - Seattle WA, US
Jane A. Gross - Seattle WA, US
Jennifer Visich - Seattle WA, US
Ivan Nestorov - Issaquah WA, US
Alain Munafo - Tartegnin, CH
Orestis Papasouliotis - Geneva, CH
Claudia Pena Rossi - Geneva, CH
International Classification:
A61K 39/395
A61P 37/00
US Classification:
4241781
Abstract:
In various embodiments, the present invention provides methods, compositions, dosing, and administration schedules for treatment of autoimmune diseases, including systemic erythematosus (SLE), for example, comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule such as atacicept. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BLyS and APRIL, in particular the use of multiple administrations of the fusion molecule at relatively low dose over the course of the treatment.

Methods For Treating Autoimmune Diseases Using A Taci-Ig Fusion Molecule

View page
US Patent:
20070274984, Nov 29, 2007
Filed:
May 15, 2007
Appl. No.:
11/748978
Inventors:
Herve Broly - Saint Selve, FR
Jennifer Visich - Seattle WA, US
Ivan Nestorov - Issaquah WA, US
Sharon Busby - Seattle WA, US
Jane Gross - Seattle WA, US
Assignee:
ARES TRADING S.A. - Aubonne
ZYMOGENETICS, INC. - Seattle WA
International Classification:
A61K 39/395
US Classification:
424131100
Abstract:
In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.

Methods Of Administering Beta7 Integrin Antagonists

View page
US Patent:
20220403033, Dec 22, 2022
Filed:
Feb 3, 2022
Appl. No.:
17/592154
Inventors:
- South San Francisco CA, US
Eric Stefanich - Emerald Hills CA, US
Meina Tang - Fremont CA, US
Jennifer Visich - San Francisco CA, US
Marna Williams - Palo Alto CA, US
Sharon O'Byrne - Burlingame CA, US
Assignee:
GENENTECH, INC. - South San Francisco CA
International Classification:
C07K 16/28
A61P 1/04
Abstract:
Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.

Methods Of Administering Beta7 Integrin Antagonists

View page
US Patent:
20210238288, Aug 5, 2021
Filed:
Feb 4, 2020
Appl. No.:
16/781647
Inventors:
- South San Francisco CA, US
Eric Stefanich - Emerald Hills CA, US
Meina Tang - Fremont CA, US
Jennifer Visich - San Francisco CA, US
Marna Williams - Palo Alto CA, US
Sharon O'Byrne - Burlingame CA, US
Assignee:
GENENTECH, INC. - South San Francisco CA
International Classification:
C07K 16/28
A61P 1/04
Abstract:
Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.

Methods Of Administering Beta7 Integrin Antagonists

View page
US Patent:
20140120084, May 1, 2014
Filed:
Sep 24, 2013
Appl. No.:
14/035811
Inventors:
- SOUTH SAN FRANCISCO CA, US
Eric Stefanich - Emerald Hills CA, US
Meina Tang - Fremont CA, US
Jennifer Visich - San Francisco CA, US
Marna Williams - Palo Alto CA, US
Sharon O'Byrne - Burlingame CA, US
Assignee:
GENENTECH, INC. - SOUTH SAN FRANCISCO CA
International Classification:
A61K 39/395
A61K 31/519
A61K 31/52
C07K 16/28
A61K 31/196
US Classification:
4241331, 4241421, 4241431
Abstract:
Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.
Control profile
Jennifer E Visich from Boulder, CO, age ~56 Get Report